

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Clarity Pharmaceuticals Ltd
ABN 36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Colin David Biggin
Date of last notice	14 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
Date of change	1 August 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<ul style="list-style-type: none"> • 1,801,304 fully paid ordinary shares • 600,000 options exercisable at \$0.605 each on or before 1 July 2024 • 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024 • 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024 • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025. • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028
<p>Class</p>	<p>Options and Shares</p>
<p>Number acquired</p>	<p>542,835 fully paid ordinary shares</p>
<p>Number disposed</p>	<p>600,000 options exercisable at \$0.605 each on or before 5 August 2024</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>\$363,000 being exercise price on options issued.</p>
<p>No. of securities held after change</p>	<ul style="list-style-type: none"> • 2,344,139 fully paid ordinary shares • 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024 • 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024 • 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025. • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028
<p>Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small></p>	<p>Exercise of options on a cashless basis applying a share price of \$6.3501 being 5 day VWAP prior to instruction to exercise.</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.